Diagnostic Workup for a Patient with High Levels of Bence Jones Protein
Initial Diagnostic Evaluation
- A patient with high levels of Bence Jones protein requires immediate comprehensive evaluation for multiple myeloma or other plasma cell disorders, with prompt initiation of appropriate therapy to prevent renal damage and other complications, as recommended by the American College of Physicians 1
- Complete blood count with differential should be performed to assess for anemia, which is the most frequent and reliable indicator of disease progression, according to the American Society of Clinical Oncology 2
- Comprehensive metabolic panel including serum creatinine, calcium, and albumin should be evaluated to assess for renal impairment and hypercalcemia, as suggested by the International Myeloma Society 3
- Serum protein electrophoresis (SPEP) and immunofixation (SIFE) should be performed to identify and quantify monoclonal proteins, as recommended by the European Society for Medical Oncology 4, 3
- Serum free light chain assay should be used to determine kappa/lambda ratio and quantify the involved light chain, according to the National Comprehensive Cancer Network 4, 1
- 24-hour urine collection for total protein quantification, electrophoresis, and immunofixation should be performed to confirm and quantify Bence Jones proteinuria, as suggested by the American Society of Nephrology 3, 1
- Bone marrow aspirate and biopsy with immunohistochemistry should be performed to determine plasma cell percentage and clonality, according to the World Health Organization 3
- Cytogenetic studies including FISH for prognostic markers (17p13, t(4;14), t(14;16)) should be performed, as recommended by the International Myeloma Society 3
- Complete skeletal survey including spine, pelvis, skull, humeri, and femurs should be performed, according to the American College of Radiology 3
- Consider MRI of thoracic-lumbar spine and pelvis for better assessment of bone involvement, as suggested by the European Society for Medical Oncology 2
- Serum β2-microglobulin and lactate dehydrogenase should be evaluated for prognostic assessment, according to the National Comprehensive Cancer Network 3
Differential Diagnosis
- With high levels of kappa Bence Jones protein, the most likely diagnoses include multiple myeloma with light chain cast nephropathy, as suggested by the International Myeloma Society 4
- Light chain amyloidosis is also a possible diagnosis, according to the European Society for Medical Oncology 4
- Monoclonal immunoglobulin deposition disease and Waldenström's macroglobulinemia are other potential diagnoses, as recommended by the American Society of Clinical Oncology 4, 5
- Monoclonal gammopathy of renal significance (MGRS) should also be considered, according to the National Kidney Foundation 4
Renal Assessment
- Calculate estimated glomerular filtration rate (eGFR) using CKD-EPI formula, which provides better prognostic value than MDRD in myeloma patients, as recommended by the National Kidney Foundation 6
- Assess for signs of acute kidney injury, which would require urgent intervention, according to the American Society of Nephrology 7
- Consider renal biopsy if the cause of renal impairment is unclear or if MGRS is suspected, as suggested by the European Renal Association 4, 1
- Evaluate for hyperviscosity syndrome with fundoscopic examination, especially with high levels of monoclonal protein, according to the American Society of Hematology 5
Treatment Considerations
- For patients with evidence of light chain cast nephropathy, initiate bortezomib-based regimens promptly to reduce production of nephrotoxic light chains, as recommended by the International Myeloma Society 7, 1
- Consider daratumumab combined with bortezomib, cyclophosphamide, and dexamethasone (D-VCD) for rapid reduction of light chains, according to the European Society for Medical Oncology 7
- Ensure adequate hydration and consider urine alkalinization to minimize further renal damage, as suggested by the National Comprehensive Cancer Network 6, 7
- For patients with hyperviscosity, consider plasmapheresis concomitantly with systemic therapy, according to the American Society of Apheresis 5
- In cases of severe renal impairment, bortezomib and dexamethasone can be administered without dose adjustment, as recommended by the International Myeloma Society 7, 1
Monitoring
- Use the same serum free light chain assay throughout treatment to ensure consistent results, according to the National Comprehensive Cancer Network 4, 1
- Monitor renal function regularly with serum creatinine and eGFR, as recommended by the American Society of Nephrology 6, 1
- Follow serum and urine monoclonal protein levels to assess treatment response, according to the International Myeloma Society 3